Novartis
- Revenue$52.9 BFY, 2021
- Market CapitalizationCHF193.4 B2022-05-17
OverviewSuggest Edit
Novartis is a company that researches, develops, manufactures, and markets healthcare products. It comprises 2 global operation divisions: Innovative Medicines and Sandoz. The Innovative Medicines division offers patented prescription medicines, commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz division provides active ingredients and finished dosage forms of pharmaceuticals in the areas of the cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, and respiratory.
| Type | Public | |
| Founded | 1996 | |
| HQ | Basel, CH | Map |
| Website | novartis.com | |
| Overall Culture | A+ | More |
Recent NewsAll News
- Global Osteoarthritis (IA Injections, NSAIDs & Analgesics) Market Research Report 2022-2026 Featuring Johnson & Johnson, Novartis, Bayer, GlaxoSmithKline, Pfizer and Sanofi
- Novartis suspends delivery of cancer treatment as it address potential production issues
- Global AI in Pharma Market Report (2022 to 2031) - Featuring Novartis, Merck and GNS Healthcare Among Others
- Tact.ai Establishes Customer Advisory Board, Names Former Novartis Pharma Global CIO and SVP Andreas Müller as Advisor
Key People/Management at Novartis
Vasant Narasimhan
Chief Executive Officer
Joerg Reinhardt
Chairman
Harry Kirsch
Chief Financial Officer
Klaus Moosmayer
Chief Ethics, Risk & Compliance Officer
Richard Saynor
Chief Executive Officer of Sandoz
Shannon Thyme Klinger
Chief Legal Officer
Novartis Office Locations
Novartis has offices in Basel, Pratteln, Rotkreuz ZG, Stein and in 167 other locations
Basel, CH (HQ)
Novartis Forum 1, Fabrikstrasse 6
Basel, CH
210, Lichtstrasse 35
Basel, CH
Fabrikstrasse 2
Pratteln, CH
Schweizerhalle, Rheinstrasse 52
Rotkreuz ZG, CH
Suurstoffi 14
Stein, CH
Schaffhauserstrasse
Novartis Financials and Metrics
Novartis Revenue
Novartis's revenue was reported to be $52.88 b in FY, 2021
| USD | |
|---|---|
Revenue (FY, 2021) | 52.9b |
Gross profit (FY, 2021) | 45.1b |
Net income (FY, 2021) | 24.0b |
EBITDA (FY, 2021) | 33.2b |
EBIT (FY, 2021) | 27.0b |
Market capitalization (17-May-2022) | 193.4b |
Closing stock price (17-May-2022) | 87.4 |
Cash (31-Dec-2021) | 12.4b |
EV | 212.0b |
Novartis's current market capitalization is CHF193.4 b.
- Source: Company Filings
Annual
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Revenue | 53.2b | 50.5b | 49.9b | 52.9b |
Cost of goods sold | (11.7b) | (9.4b) | (8.6b) | (9.7b) |
Gross profit | 43.2b | 43.1b | 43.0b | 45.1b |
R&D expense | (9.1b) | (9.5b) | (9.0b) | (9.5b) |
Quarterly
| USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 11.2b | 14.1b | 12.5b | 12.3b | 12.0b | 12.5b | 12.4b | 13.6b | 13.4b |
Cost of goods sold | (1.8b) | (3.2b) | (4.9b) | (2.3b) | (1.7b) | (2.0b) | (2.3b) | (4.2b) | (788.0m) |
Gross profit | 9.8b | 11.6b | 7.8b | 10.7b | 10.3b | 10.9b | 10.7b | 9.9b | 13.0b |
R&D expense | (2.3b) | (2.2b) | (2.2b) | (2.1b) | (2.4b) | (2.1b) | (2.4b) | (2.4b) | (2.4b) |
- Source: Company Filings
Annual
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Cash | 13.3b | 11.1b | 9.7b | 12.4b |
Accounts Receivable | 8.7b | 8.3b | 8.2b | 8.0b |
Prepaid Expenses | 1.1b | 1.2b | 1.2b | 1.4b |
Inventories | 7.0b | 6.0b | 7.1b | 6.7b |
Quarterly
| USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 6.8b | 10.0b | 8.4b | 4.5b | 5.9b | 9.0b | 3.8b | 5.1b | 7.2b |
Accounts Receivable | 7.6b | 8.0b | 7.8b | 8.5b | 7.6b | 8.1b | 8.3b | 8.4b | 8.4b |
Prepaid Expenses | 233.0m | 279.0m | 244.0m | 254.0m | 308.0m | 226.0m | 216.0m | 254.0m | 255.0m |
Inventories | 5.7b | 6.1b | 6.1b | 6.4b | 6.9b | 7.1b | 7.0b | 7.1b | 6.9b |
- Source: Company Filings
Annual
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Net Income | 12.6b | 7.1b | 8.1b | 24.0b |
Depreciation and Amortization | 6.9b | 5.5b | 6.1b | 5.8b |
Inventories | (533.0m) | (382.0m) | (543.0m) | 81.0m |
Accounts Payable | 309.0m | 553.0m | (324.0m) | (21.0m) |
Quarterly
| USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | 1.9b | 4.0b | 6.0b | 2.2b | 4.0b | 6.0b | 2.1b | 2.9b | 7.7b |
Depreciation and Amortization | 1.4b | 2.5b | 3.9b | 1.3b | 3.0b | 4.6b | 1.6b | 1.4b | 4.4b |
- Source: Company Filings
| USD | FY, 2018 |
|---|---|
Revenue/Employee | 424.8k |
Novartis Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Gyroscope Therapeutics | December 22, 2021 | $1.5 b |
| Arctos Medical | September 17, 2021 | |
| Cellerys | June 01, 2021 | |
| Cadent Therapeutics | December 17, 2020 | $770 m |
| Vedere Bio | October 29, 2020 | $280 m |
| Vedere Bio ll | October 29, 2020 | $280 m |
| Amblyotech | April 21, 2020 | |
| The Medicines Company | November 25, 2019 | $9.7 b |
| Xiidra | May 09, 2019 | $1.9 b |
| Novartis Inflammasome Research | April 02, 2019 | $1.58 b |
Novartis Revenue Breakdown
Novartis revenue breakdown by business segment: 18.7% from SANDOZ, 83.2% from INNOVATIVE MEDICINES and -1.8% from Other
Novartis Cybersecurity Score
Novartis Environment, Social & Governance (ESG) Ratings
Novartis Online and Social Media Presence
299.81k Twitter followers
Novartis has 299.81k Twitter Followers. The number of followers has increased 0.1% month over month and increased 0.4% quarter over quarter
Novartis's Trends
Twitter Engagement Stats for @novartis
12.7k
Tweets
565
Following
299.8k
Followers
32
Tweets last 30 days
10.8
Avg. likes per Tweet
37.5%
Tweets with engagement
Novartis Company Culture
Overall Culture
A+
78/100
CEO Rating
A+
88/100
Compensation
A+
90/100
Diversity
A+
83/100
Novartis News and Updates
May 18, 2022
Global Osteoarthritis (IA Injections, NSAIDs & Analgesics) Market Research Report 2022-2026 Featuring Johnson & Johnson, Novartis, Bayer, GlaxoSmithKline, Pfizer and Sanofi
DUBLIN, May 18, 2022 /PRNewswire/ -- The "Global Osteoarthritis Market (IA Injections, NSAIDs & Analgesics): Insights, Trends & Forecast (2022-2026)" report has been added to ResearchAndMarkets.com's offering. The global osteoarthritis market revenues are forecasted to touch US$12.14...
May 05, 2022
Novartis suspends delivery of cancer treatment as it address potential production issues
The U.S.-listed shares of Novartis AG fell 2.6% in afternoon trading Thursday, after the Switzerland-based drug maker said it was "temporarily" suspending delivery of its cancer treatments Lutathera and Pluvicto in the U.S., as part of a quality review of its production sites in Millburn, New Jers…
May 05, 2022
Global AI in Pharma Market Report (2022 to 2031) - Featuring Novartis, Merck and GNS Healthcare Among Others
Dublin, May 05, 2022 (GLOBE NEWSWIRE) -- The "AI In Pharma Global Market Report 2022, By Technology, Drug Type, Application" report has been added to ResearchAndMarkets.com's offering. This report provides strategists, marketers and senior management with the critical information they need to asse…
May 04, 2022
Tact.ai Establishes Customer Advisory Board, Names Former Novartis Pharma Global CIO and SVP Andreas Müller as Advisor
SUNNYVALE, Calif., May 4, 2022 /PRNewswire/ -- Tact.ai, the customer engagement company for life sciences, announced today that former Novartis Pharma Global CIO and SVP, Andreas Müller, has joined the company as an Advisor. His role will focus on working with commercial and medical...
May 04, 2022
New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients
Basel, May 4, 2022 — Novartis today announced updated median overall survival (OS) results for Kisqali® (ribociclib) in combination with fulvestrant in the first-line subgroup of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanc…
April 29, 2022
Global Gastro Esophageal Reflux Disease Drug Market to 2027 - Featuring GlaxoSmithKline, Medtronic and Novartis Among Others
Dublin, April 29, 2022 (GLOBE NEWSWIRE) -- The "Global Gastro Esophageal Reflux Disease (GERD) Drug Market 2021-2027" report has been added to ResearchAndMarkets.com's offering. The global Gastro Esophageal Reflux Disease (GERD) market is anticipated to grow at a considerable CAGR during the forec…
Novartis Frequently Asked Questions
When was Novartis founded?
Novartis was founded in 1996.
Who are Novartis key executives?
Novartis's key executives are Vasant Narasimhan, Joerg Reinhardt and Harry Kirsch.
How many employees does Novartis have?
Novartis has 110,000 employees.
What is Novartis revenue?
Latest Novartis annual revenue is $52.9 b.
What is Novartis revenue per employee?
Latest Novartis revenue per employee is $480.7 k.
Who are Novartis competitors?
Competitors of Novartis include Merck Group, Bausch + Lomb and Immunomedics.
Where is Novartis headquarters?
Novartis headquarters is located at Novartis Forum 1, Fabrikstrasse 6, Basel.
Where are Novartis offices?
Novartis has offices in Basel, Pratteln, Rotkreuz ZG, Stein and in 167 other locations.
How many offices does Novartis have?
Novartis has 186 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies